News & Press

MindMaze Therapeutics Narrows Losses and Prepares for Commercial Takeoff in 2026

BioAlps4/30/2026·04/30/26🌐 Europe

Summary

Swiss-based MindMaze reported CHF 0.6 million in revenue for 2025 with a net loss of CHF 9.9 million. The company completed a reverse merger with Relief Therapeutics in December 2025 and appointed CEO Zach Henderson to drive commercialization. MindMaze's platform has collected 1.2 billion data points monthly from approximately 35,000 patient users.

Why it matters

MindMaze's transition to a publicly listed entity and its focus on US commercial deployment signal a maturation of European digital neurotherapeutics. The company's dataset of 1.2 billion monthly data points creates a competitive moat in AI-driven neurorehabilitation.

#BCI#Stroke Rehabilitation#Europe#Industry#AI

Want the full NeurotechMag Pro intelligence database?

Access 800+ papers, trials, patents, funding rounds and news items — updated daily.

Start free trial

Already a member? Sign in